# Vertex Pharmaceuticals Phase 3 RAINIER Hits Primary Endpoint in IgA Nephropathy

> Vertex Pharmaceuticals' povetacicept cut proteinuria 49.8% versus placebo at Week 36 in Phase 3 RAINIER, with an FDA decision set for November 30, 2026.

- Published: 2026-10-23T18:03:50+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-23/vertex-rainier-igan-endpoint
- Source: [TradingView](https://www.tradingview.com/news/tradingview:85e243ba8418b:0-vertex-pharmaceuticals-incorporated-vrtx-phase-3-rainier-meets-primary-endpoint-in-igan/)

## Key takeaways

- Povetacicept reduced proteinuria by 49.8% versus placebo at Week 36 in the Phase 3 RAINIER trial, with a P value below 0.0001.
- Both secondary endpoints were met, and 42.2% of patients reached a UPCR below 0.5 g/g.
- The FDA's accelerated approval review of povetacicept carries a PDUFA date of November 30, 2026.

[Vertex Pharmaceuticals](https://akta.pro/company-profiles/00004y4/vertex-pharmaceuticals) reported that its Phase 3 RAINIER trial of povetacicept met its primary endpoint in IgA nephropathy, cutting proteinuria by 49.8% versus placebo at Week 36. [TradingView](https://www.tradingview.com/news/tradingview:85e243ba8418b:0-vertex-pharmaceuticals-incorporated-vrtx-phase-3-rainier-meets-primary-endpoint-in-igan/) carried the interim results, which were presented with publication at NEJM/ASN. The company said the result was statistically significant, with a P value below 0.0001.

## What the RAINIER Interim Results Showed

Vertex Pharmaceuticals said povetacicept reduced proteinuria by 49.8% compared with placebo at Week 36, and by 52.0% from baseline at the same point. Both secondary endpoints were met, covering Gd-IgA1 and hematuria. In addition, 42.2% of patients reached a UPCR below 0.5 g/g, a threshold aligned with KDIGO guidance.

The company said the safety profile was generally well tolerated, with no serious adverse events related and no opportunistic infections. Vertex Pharmaceuticals is a Boston-based biotech founded in 1989 that develops small-molecule and gene-editing therapies for serious diseases, serving rare-disease patients through a cystic fibrosis franchise, the CRISPR-based Casgevy for sickle cell disease, and a pipeline spanning pain, kidney and Type 1 diabetes.

## Povetacicept's Regulatory Path at the FDA

According to akta.pro [company records](https://akta.pro/company-data), the FDA accepted the povetacicept BLA in June 2026 with a PDUFA date of November 30, 2026, advancing the Alpine-acquired asset toward a commercial launch in IgA nephropathy. The same records list Vertex Pharmaceuticals revenue of $12 billion for fiscal 2025, up 8.9% year over year, and Q1 2026 revenue of $2.99 billion. Net income was approximately $4 billion for fiscal 2025, at a 32.7% net margin, and Casgevy recorded 5,000 patient initiations globally across approved countries.

## Earlier Vertex Pharmaceuticals Moves

Vertex Pharmaceuticals named Daniel J. Brennan to its board of directors effective October 20, 2026, The future of trading reported. The Motley Fool reported that Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals for about $10 billion in cash, adding Palsonify for acromegaly and Atumelnant for hormonal disorders. FinanzNachrichten.de reported that Vertex's Casgevy generated over $100 million in 2025.

## Vertex's Next Data and Decision Dates

The FDA's accelerated approval review of povetacicept is under way, with a PDUFA date of November 30, 2026. Durability on eGFR slope at 104 weeks is also being tracked.

## Companies in this story

- [Vertex Pharmaceuticals company profile](https://akta.pro/company-profiles/00004y4/vertex-pharmaceuticals) · website: http://www.vrtx.com

---
News for Agent · https://newsforagent.com/llms.txt